DDI Webinar Series: “Understanding Abuse Deterrent Opioids”- December 8, 2016

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all healthcare professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!

 

On December 8, 2016,CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: Understanding Abuse Deterrent Opioids. As part of the FDA’s overarching Opioid Action Plan, the FDA is encouraging the development of opioid formulations with abuse-deterrent properties to help combat the opioid epidemic. Dr. Scott K. Winiecki, MD is the Acting Team Lead for the Safe Use Team in the Professional Affairs and Stakeholder Engagement group within the Center for Drug Evaluation and Research and discussed the various properties of abuse-deterrent opioids, how the FDA evaluates and determines labeling for abuse-deterrent properties, and the real-world impact these formulations have on healthcare providers.

 

 

View Webinar: https://collaboration.fda.gov/p8wssbjvc17/

 

Download Presentation Slides: Understanding Abuse Deterrent Opioids (PDF - 343KB)

 

Activity Outline and Continuing Education Information: Understanding Abuse Deterrent Opioids (PDF - 43KB)

---

If you have never attended an Adobe Connect meeting before:

Test your connection: https://collaboration.fda.gov/common/help/en/support/meeting_test.htm

Get a quick overview: http://www.adobe.com/go/connectpro_overview 

Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

ResourcesForYou

• Division of Drug Information (DDI) Webinars
• CDER Webinars